Vergelijking
Cagrilintide vs. Lixisenatide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
1415456-99-3
320367-13-3
Molecuulmassa
4253.7 g/mol
4858.5 g/mol
Halfwaardetijd
168 h
3 h
Sequentie
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Werkingsmechanisme
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
5
waarvan bij mensen
3
5
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Cagrilintide and Lixisenatide?
- Cagrilintide is classified as "Metabool", while Lixisenatide is classified as "Metabool". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Lixisenatide?
- The highest available evidence level is "Humane RCT" for Cagrilintide and "Humane RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Lixisenatide in Germany and the United States?
- Duitsland: Cagrilintide — Niet goedgekeurd, Lixisenatide — Op recept. Verenigde Staten: Cagrilintide — Niet goedgekeurd, Lixisenatide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.